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Reedik Mägi,1,25 Lili Milani,1,25,* and João Fadista12,23,24,25SummaryHypersensitivity reactions to drugs are often unpredictable and can be life threatening, underscoring a need for understanding their un-
derlying mechanisms and risk factors. The extent to which germline genetic variation influences the risk of commonly reported drug
allergies such as penicillin allergy remains largely unknown. We extracted data from the electronic health records of more than
600,000 participants from the UK, Estonian, and Vanderbilt University Medical Center’s BioVU biobanks to study the role of genetic
variation in the occurrence of self-reported penicillin hypersensitivity reactions. We used imputed SNP to HLA typing data from these
cohorts to further fine map the human leukocyte antigen (HLA) association and replicated our results in 23andMe’s research
cohort involving a total of 1.12 million individuals. Genome-wide meta-analysis of penicillin allergy revealed two loci, including one
located in the HLA region on chromosome 6. This signal was further fine-mapped to the HLA-B*55:01 allele (OR 1.41 95%
CI 1.33–1.49, p value 2.04 3 1031) and confirmed by independent replication in 23andMe’s research cohort (OR 1.30 95%
CI 1.25–1.34, p value 1.00 3 1047). The lead SNP was also associated with lower lymphocyte counts and in silico follow-up suggests
a potential effect on T-lymphocytes at HLA-B*55:01. We also observed a significant hit in PTPN22 and the GWAS results correlated
with the genetics of rheumatoid arthritis and psoriasis. We present robust evidence for the role of an allele of the major histocompat-
ibility complex (MHC) I gene HLA-B in the occurrence of penicillin allergy.Introduction
Adverse drug reactions (ADRs) are common in clinical
practice and are associated with high morbidity and
mortality. A meta-analysis of prospective studies in the
US revealed the incidence of serious ADRs to be 6.7%
among hospitalized patients and the cause of more
than 100,000 deaths annually.1 In Europe, ADRs are
responsible for 3.5% of all hospital admissions, with
10.1% of patients experiencing ADRs during hospitaliza-
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ADRs are typically divided into two types of reactions.
Type A reactions are more predictable and related to the
pharmacological action of a drug, whereas type B reactions
are idiosyncratic, less predictable, largely dose indepen-
dent, and typically driven by hypersensitivity reactions
involving the immune system.5 Although type B reactions
are less frequent (<20%) than type A reactions, they tend
to be more severe and more often lead to the withdrawal
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causes of type B reactions are antibiotics,5 typically from
the beta-lactam class, with the prevalence of penicillin al-
lergy estimated to be as high as 25% in some settings.7,8
Despite the relative frequency of such reactions, there are
very few studies of the genetic determinants of penicillin
allergy.9,10 This underscores the need for a better under-
standing of the mechanisms and risk factors, including
the role of genetic variation, that contribute to these
reactions.
The increasing availability of genetic and phenotypic
data in large biobanks provides an opportune means for
investigating the role of genetic variation in drug-induced
hypersensitivity reactions. In the present study, we sought
to identify genetic risk factors underlying penicillin-
induced hypersensitivity reactions by harnessing data
from the Estonian Biobank (EstBB), UK Biobank (UKBB),
and Vanderbilt University Medical Center’s (VUMC) DNA
Biobank (BioVU), with further replication in the 23andMe
research cohort.Subjects and Methods
Study Subjects and Phenotype Definitions
We studied individual-level genotypic and phenotypic
data of 52,000 participants from the Estonian Biobank
(EstBB), 500,000 participants from UK Biobank (UKBB),
and a subset of 67,323 individuals from BioVU, the
VUMC biorepository linked to de-identified electronic
health records with self-reported European ancestry.11
EstBB, UKBB, and BioVU are population- or hospital-based
cohorts, providing a rich variety of phenotypic and health-
related information collected for each participant. All par-
ticipants have signed a consent form to allow follow-up
linkage. In UKBB and EstBB we extracted information on
penicillin allergy by searching the records of the partici-
pants for the Z88.0 ICD10 code indicating patient-reported
allergy status to penicillin. Information on phenotypic fea-
tures like age and gender were obtained from the biobank
recruitment records. We also extracted likely penicillin al-
lergies in EstBB from the recruitment questionnaires and
free text fields of the electronic health records (EHRs) using
a rule-based approach (see Supplemental Subjects and
Methods for further details). In BioVU there were no re-
cords of Z88.0 diagnoses, so we used drug allergy labels
from the allergy section of the EHRs, which includes
adverse drug reactions reported by an individual or
observed by the health care provider (Supplemental Sub-
jects and Methods).
This study was approved by the Research Ethics Com-
mittee of the University of Tartu (Approval number 288/
M-18) and conducted using the UK Biobank Resource un-
der Application Number 11867.Genome-wide Study and Meta-analysis
The details on genotyping, quality control, and imputa-
tion are fully described elsewhere for EstBB12,13 andThe AmericaUKBB;14 see Supplemental Subjects and Methods for
further details. In EstBB, we conducted the penicillin
GWAS on 44,348 individuals, including 1,320 case subjects
with self-reported allergy to beta-lactam drugs or penicillin
and 43,028 control subjects. In the UKBB, GWAS on peni-
cillin allergy (defined using ICD-10 code Z88.0) was per-
formed among 15,782 case subjects and 370,782 control
subjects. In BioVU, GWAS on penicillin allergy (defined us-
ing drug allergy labels in the EHR) was performed among
12,294 case subjects and 38,284 control subjects. For all
three cohorts, the GWAS was performed with SAIGE15
including related individuals and adjusting for the first
ten principal components (PCs) of the genotype matrix,
as well as for age or birth year, sex (see Supplemental Sub-
jects and Methods), and in BioVU, additionally for EHR
length (years). We performed meta-analysis of 19,724,685
markers (with minor allele frequency [MAF] > 0.1%) and
SNP effect estimates and their standard errors were com-
bined in a fixed effects model with the inverse variance
weighted method using the METAL software.16 Results
were visualized with the R software (3.3.2) (see Web
Resources).
HLA-Typing
HLA imputation of the EstBB genotype data was performed
at the Broad Institute using the SNP2HLA tool.17 The
imputation was done for genotype data generated on the
Global Screening Array v1, and after quality control the
four-digit HLA alleles of 22,554 individuals were used for
analysis. In UKBB we used four-digit imputed HLA data
released by UKBB (see Web Resources).14 The imputation
process, performed using HLA*IMP:02,18 is described fully
elsewhere14 and in the Supplemental Subjects and
Methods. For the BioVU cohort, four-digit HLA-typing
was imputed from SNP data with the SNP2HLA tool (Sup-
plemental Subjects and Methods).
We performed separate additive logistic regression anal-
ysis with the called HLA alleles using R glm function in
EstBB, UKBB, and BioVU (see Supplemental Subjects and
Methods for further details). Meta-analysis of 164 HLA al-
leles present in all three cohorts was performed with the
GWAMA software tool.19 A Bonferroni-corrected p value
threshold of 3.053 104 was applied based on the number
of tested alleles (0.05/164).
For detection of the strongest tagging SNP for the HLA-
B*55:01 allele, we calculated Pearson correlation coeffi-
cients between the HLA-B*55:01 allele and all the SNPs
within 550 kb of the HLA-B region using the cor function
in R (3.3.2) (see Web Resources).
HLA-B*55:01 Replication
We performed replication analysis of the HLA-B*55:01
allele in 87,996 case subjects and 1,031,087 control sub-
jects of European ancestry (close relatives removed) from
the 23andMe research cohort using an additive logistic
regression model (see details in the Supplemental Subjects
and Methods). The self-reported phenotype of penicillinn Journal of Human Genetics 107, 612–621, October 1, 2020 613
allergy was defined based on questionnaire data as a posi-
tive allergy test or allergic symptoms related to penicillin
exposure (see Supplemental Subjects and Methods for
further details). Meta-analysis of the HLA-B*55:01 associa-
tion across the four cohorts was performed with the
GWAMA software tool19 and results were visualized with
R software (3.3.2) (see Web Resources).Results
Genome-wide Association Analysis of Penicillin Allergy
To discover genetic factors that may predispose to peni-
cillin allergy, we conducted a genome-wide association
study (GWAS) of 19.7 million single-nucleotide polymor-
phisms (SNPs) and insertions/deletions in UKBB, EstBB,
and BioVu (MAF in all cohorts > 0.1%) among individuals
with European ancestry. Case subjects were defined as
participants with a Z88.0 ICD10 code (‘‘Allergy status to
penicillin’’), which indicates a reported history of peni-
cillin allergy (previously ICD9 ‘‘personal history of allergy
to penicillin’’). In total, we identified 15,782 individuals
(4.1% of the total cohort size of 386,564) in UKBB with
this diagnostic code. However, the corresponding number
of case subjects in EstBB was only 7 (0.01% of the total
cohort size of 51,936) and zero in BioVu, suggesting het-
erogeneity in the use of the Z88.0 ICD10 code in different
countries. We therefore also identified participants that
had reported drug allergy at recruitment in EstBB and
categorized the EstBB self-reported reactions by drug class,
using the Anatomical Therapeutic Chemical (ATC) Classi-
fication System code J01C* (beta-lactam antibacterials,
penicillins) to match this to the respective Z88.0 ICD10
code. We also extracted 321 individuals with mentions
of penicillin allergy in the free text fields of their EHR.
This resulted in 1,320 (2.5%) case subjects with penicillin
allergy in EstBB. We validated the approach in EstBB by
evaluating the association between the number of filled
(i.e., prescribed and purchased) penicillin (using the ATC
code J01C*) prescriptions per person and self-reported
penicillin allergy. Using Poisson regression analysis, we
identified a negative association among individuals with
self-reported allergy in EstBB on the number of filled peni-
cillin prescriptions (p value 2.41 3 1015, estimate 0.18,
i.e., 16% lower penicillin prescription count for individ-
uals with penicillin allergy). In BioVU, we used drug al-
lergy labels from the allergy section of the EHR to identify
12,294 case subjects (18.3% of the total cohort of geno-
typed individuals of 67,323), which is consistent with pre-
vious penicillin allergy reports using drug allergy labels.20
To characterize the proportion of severe reactions
(anaphylaxis) to penicillin among our phenotype, we
analyzed the self-reported reactions among 1,017 individ-
uals in EstBB and found that around 3% (n ¼ 31) of the
participants reported anaphylaxis and 4% (n ¼ 42) some
form of breathing difficulties. In the BioVU cohort, 5%
of participants (n ¼ 673 out of 12,294 with penicillin614 The American Journal of Human Genetics 107, 612–621, Octobeallergy label) reported anaphylaxis. These figures indicate
that our phenotype likely captures less-severe forms of
penicillin hypersensitivity.
We thenmeta-analyzed the results of theGWASes in these
three cohorts and identified two genome-wide significant
(p < 5 3 108) signals for penicillin allergy. The top hit on
chromosome 6 was located in the major histocompatibility
complex (MHC) region (rs114892859, MAF(EstBB) ¼ 0.7%,
MAF(UKBB) ¼ 2%, MAF(BioVU) ¼ 2%; p value 1.29 3
1029; OR 1.47 95% CI 1.38–1.57) (Figures 1A and S1, Table
S1). We also identified a further signal for rs2476601, a
missense variant in PTPN22 on chromosome 1 (p value
2.683 109; OR 1.09 95% CI 1.06–1.12).
Fine-Mapping the Penicillin Allergy-Associated HLA
Locus
To further characterize the identified association with
penicillin allergy, we performed a functional annotation
analysis with FUMA (Functional Mapping and Annota-
tion of Genome-Wide Association Studies).21 We detected
an independent intronic lead SNP for the penicillin
allergy meta-analysis (GWAS lead variant rs114892859,
p value 1.29 3 1029) in MICA (Figure 1B). When testing
the SNP for expression quantitative trait locus (eQTL) as-
sociations in blood based on data from the eQTLGen
Consortium,22 the variant appeared to be associated
with the expression levels of several nearby genes, with
the most significant being PSORS1C3 (p value 8.10 3
1062) and MICA (p value 1.21 3 1052) (Table S2). We
further performed an in silico investigation of the lead
SNP rs114892859 and its best proxy (rs144626001, the
only proxy with r2 > 0.9 in UKBB and EstBB) in HaploReg
v.4 to explore annotations and impact of the non-coding
variant.23 rs114892859 in particular had several annota-
tions indicative of a regulatory function, including its
location in both promoter and enhancer marks in T cells
and evidence of RNA polymerase II binding.24,25 Interest-
ingly, its proxy is more likely to be deleterious based on
the scaled Combined Annotation Dependent Depletion
(CADD) score (scaled score of 15.78 for rs144626001 (C/
T) and 4.47 for rs114892859 (G/T)).26,27 To assess the as-
sociation of the rs114892859 variant with self-reported
penicillin allergy in non-European ancestries, we used
the recently developed Pan-UKB resource (see Web
Resources) and retrieved summary statistics for individ-
uals of Central/South Asian, African, East Asian, and
Middle Eastern (Table S3) ancestries. We did not find an
association with penicillin allergy in these other ancestry
groups. Neither did we find any association of the
rs114892859 variant with penicillin allergy (p value
0.288; OR 0.67 95% CI 0.14–1.19) in a subset of 14,416
BioVU individuals with self-reported African ancestry,
including 1,894 case subjects and 9,539 control subjects.
Nevertheless, these sample sizes are substantially smaller
than the European-ancestry groups we studied and larger
cohorts of diverse ancestries will be needed to provide
more definitive insights.r 1, 2020
Figure 1. Manhattan Plot and HLA Locus of the Genome-wide Association Study of Penicillin Allergy
The X axes indicate chromosomal positions and Y axes log10 of the p Values.
(A) Each dot represents a single-nucleotide polymorphism (SNP). The dotted line indicates the genome-wide significance (p value <
5.0 3 108) p value threshold.
(B) SNPs are colored according to their linkage disequilibrium (LD; based on the 1000 Genomes phase3 EUR reference panel) with the
lead SNP. The SNP marked with a purple diamond is the lead SNP rs114892859.Due to the high LD in theMHC region, we used imputed
SNP to HLA typing data available at four-digit resolution28
for up to 22,554, 488,377, and 67,323 individuals from the
Estonian, UK, and BioVU cohorts, respectively, to further
fine-map the identified HLA association with penicillin al-
lergy. In all cohorts a shared total of 104 alleles at four-digitThe Americalevel were present for all of the MHC class I genes (HLA-A,
HLA-B, HLA-C) and 60 alleles for three of the classical MHC
class II genes (HLA-DRB1, HLA-DQA1, HLA-DQB1). To
assess the variation in the frequencies of the HLA alleles
in different populations, we compared the obtained allele
frequencies in EstBB and UKBB (Table S4) with then Journal of Human Genetics 107, 612–621, October 1, 2020 615
frequencies of HLA alleles in different European, Asian,
and African populations reported in the HLA frequency
database (Figures S2 and S3, Table S5).
We then used an additive logistic regression model to
test for associations between different four-digit HLA al-
leles and penicillin allergy in UKBB, EstBB, and BioVU.
The results from these three cohorts were meta-analyzed,
using a Bonferroni-corrected p value threshold (0.05/
164 ¼ 3.05 3 104, where 164 is the number of meta-
analyzed HLA alleles). One of the two results that sur-
passed the threshold had discordant effects in the tested
cohorts (Table S6). The only association with the same
directional effect in all three cohorts that we detected for
penicillin allergy was the HLA-B*55:01 allele (p value
2.04 3 1031; OR 1.41 95% CI 1.33–1.49; Table S6), which
is tagged (r2> 0.95) by the GWAS lead variant rs114892859
(Table S7). We performed a separate meta-analysis for the
HLA-B*55:01 allele in all case subjects from BioVU and
EstBB (p value 1.98 3 108; OR 1.32 95% CI 1.20–1.45)
and compared it to a meta-analysis where severe reactions
of anaphylaxis were excluded. Despite the smaller sample
size, the estimates from this analysis were similar (p value
1.28 3 108; OR 1.33 95% CI 1.20–1.46), indicating that
the association is not driven by more severe hypersensitiv-
ity reactions.
Replication of the HLA-B*55:01 Association with
Penicillin Allergy
To further confirm association with penicillin allergy, we
analyzed the association of the HLA-B*55:01 allele with
self-reported penicillin allergy among 87,996 case subjects
and 1,031,087 control subjects of European ancestry from
the 23andMe research cohort. We observed an association
(p value 1.003 1047; OR 1.30 95% CI 1.25–1.34; Figure 2)
with a similar effect size as seen for the HLA-B*55:01
allele in the meta-analysis of the EstBB, UKBB, and BioVU.
Meta-analysis of estimates for HLA-B*55:01 from the dis-
covery and replication cohorts demonstrated a 33% higher
relative odds of penicillin allergy among carriers of the
allele (p value 1.15 3 1077; OR 1.33 95% CI 1.29–1.37;
Figure 2).
Further Associations at HLA-B*55:01
Finally, we used the Open Targets Genetics platform’s
UKBB PheWAS data29 to further characterize the associa-
tion of the GWAS lead variant (and HLA-B*55:01 allele
tag-SNP) rs114892859 with other traits. We found associa-
tions with lower lymphocyte counts (p value 9.213 1014,
0.098 cells per nanoliter, per allergy-increasing T allele)
and lower white blood cell counts (p value 3.17 3 109,
0.078 cells per nanoliter, per allergy-increasing T allele).
To confirm this finding, we extracted data on lymphocyte
counts from the EHR data of 4,567 EstBB participants (see
Supplemental Subjects and Methods) and observed the
same inverse association of the HLA-B*55:01 allele with
lymphocyte counts (0.148 cells per nanoliter, per T allele;
p value ¼ 0.047).616 The American Journal of Human Genetics 107, 612–621, OctobeTo investigate the possible functional impact of the HLA-
B*55:01 allele, we compared the amino acid sequence of all
the HLA-B alleles commonly present in Estonian and UK
biobank (see Supplemental Subjects and Methods). Only
one allele that was represented in our populations, HLA-
B*56:01, shared a high sequence similarity (>99%) with
HLA-B*55:01, while all the other 46 alleles shared 86.5%–
93% of the amino acids within the antigen-binding cleft
(Table S8). Further analysis revealed that HLA-B*56:01
and HLA-B*55:01 differ by only two amino acids in the
a2 domain: p.Glu152Val and p.Thr163Leu (Figure S4).
We did not observe an association between the HLA-B*
56:01 allele and penicillin allergy (p value ¼ 0.24),
which might suggest that the two amino acid differences
may have functional relevance in penicillin allergy.
However, despite the large number of case subjects in our
study, power was limited to rule out an association with
HLA-B*56:01, as it is only present at a frequency of 0.3%
in European populations.
To get closer to the possible endophenotypes tagging
the identified associations, we investigated genetic corre-
lation of self-reported penicillin allergy with studies on
autoimmune and hematological traits using LDhub (Table
S9).30 The analysis pointed toward genetic correlation (rg)
of 0.35 (p value 3.65 3 107) between self-reported peni-
cillin allergy and rheumatoid arthritis (RA). This result
was virtually unchanged when we excluded 1 Mb around
PTPN22 (rg ¼ 0.35, p value 6.13 3 106), a known RA risk
locus. Since we detected this genetic correlation between
RA and self-reported penicillin allergy, we redid the peni-
cillin allergy association analysis for the HLA-B*55:01
allele among only RA case subjects in UKBB (468 peni-
cillin allergy case subjects and 4,065 control subjects).
The effect estimate for the HLA-B*55:01 allele was similar
to that from the whole UKBB cohort (p value 0.032; OR
1.57 95% CI 1.04–2.38). Because LDhub did not have
data for psoriasis, we further used summary statistics of
the GWAS meta-analysis available for psoriasis from the
PAN UKBB resource (2,868 case subjects and 417,663 con-
trol subject subjects). The genetic correlation of the GWAS
meta-analysis of penicillin allergy with psoriasis was 0.44
(p value 0.002). In summary, our results suggest that the
self-reported penicillin allergy phenotype could be
tagging a less severe, T cell-mediated, delayed-type peni-
cillin allergy, and that it may involve an autoimmune
component.Discussion
In the present study, we identify associations of the HLA-B*
55:01 allele and a missense variant rs2476601 in PTPN22
with self-reported penicillin allergy using data from four
large cohorts: UKBB, EstBB, BioVu, and 23andMe. Hyper-
sensitivity or allergic reactions to medications are type B
adverse drug reactions that are known to be mediated by
the immune system. One major driver of hypersensitivityr 1, 2020
Figure 2. HLA-B*55:01 Allele Association
with Self-Reported Penicillin Allergy
The odds ratios (dots) and 95% confidence
intervals (CI, horizontal lines) for the associ-
ation of the HLA allele with penicillin al-
lergy are presented. The plot is annotated
with p values and case-control numbers.
Color coding indicates the results for dis-
covery cohorts UKBB (black), EstBB (blue),
and BioVU (purple) and replication results
of the HLA-B*55:01 allele in the 23andMe
research cohort (green). Results of the
meta-analysis of all four cohorts is indicated
with a diamond (red). Self-reported peni-
cillin allergy is defined as ICD10 code
Z88.0 (UKBB), reported drug allergy labels
from the allergy section of the EHR (BioVU),
reported allergy to drugs in ATC J01C* class
(EstBB), or reported allergy to penicillin
(23andMe).reactions is thought to be the HLA system. HLA class I al-
leles are expressed on all nucleated cells. HLA is the most
polymorphic region of the human genome that has played
a major evolutionary role in adaptive immune responses
through presentation of foreign peptides to T cell receptors
that in the case of an HLA-class I restricted response leads
to activation of CD8þ T cells.31 Genetic variation in the
HLA region alters the shape of the peptide-binding pocket
in HLAmolecules and enables their binding to a vast num-
ber of different peptides—a crucial step in the adaptive im-
mune response.32 However, this ability of HLA molecules
to bind a wide variety of peptides may also facilitate bind-
ing of exogenousmolecules such as drugs, potentially lead-
ing to off-target drug effects and immune-mediated
ADRs.33 The precise mechanism of most HLA-drug interac-
tions remains unknown, but it seems that T cell activation
is necessary for the majority of HLA-mediated ADRs.33–35
Despite the increasing evidence for a role of the HLA
system in drug-induced hypersensitivity, much is still un-
clear mechanistically as to how genetic variation in the
HLA region predisposes to specific drug reactions.
Penicillin is the most common cause of drug allergy,
with clinical manifestations ranging from relatively
benign cutaneous reactions to life-threatening systemic
syndromes.7,8 There is a previous GWAS on the immediate
type of penicillin allergy, where a borderline genome-wide
significant protective association of an allele of the MHC
class II gene HLA-DRA was detected and further replicated
in a different cohort.36 Here we detect a robust association
between self-reported penicillin allergy and an allele of the
MHC class I gene HLA-B. The allele and its tag-SNP were
also associated with lower lymphocyte counts and overlap-
ped with T cell regulatory annotations. This raises the pos-
sibility that the variant may predispose to a T cell-mediated
process that could lead to a delayed penicillin reaction
through a heterologous response from an HLA-B*55:01
restricted immune response that occurred earlier in life to
a prevalent pathogen or an infection or disease interaction.
MHC I molecules are expressed by almost all cells and pre-The Americasent peptides to cytotoxic CD8þ T cells, whereas MHC II
molecules are expressed by antigen-presenting cells to
present peptides to CD4þ T helper lymphocyte.32,35 There
are several examples of MHC I alleles associated with drug-
induced hypersensitivity mediated by CD8þ T cells.35,37,38
The involvement of T cells in delayed hypersensitivity re-
actions has been shown by isolating drug-reactive T cell
clones,39 and cytotoxic CD8þ T cells have been shown to
be relevant especially in allergic skin reactions.40–42 More
than 20 years ago, CD8þ T cells reactive to penicillin
were isolated from patients with delayed type of hypersen-
sitivity to penicillin.43 The association with the HLA-B*
55:01 allele detected in our studymight be a relevant factor
in this established connection with CD8þ T cells as HLA-
B07-supertype alleles that share peptide binding specific-
ities with HLA-B*55:01 have previously been associated
with nevirapine-induced rash.44 The underlying mecha-
nism in penicillin allergy remains a question and various
models have been proposed for T cell-mediated hypersen-
sitivity.37,42 For example, the hapten model suggests that
drugs may alter proteins and thereby induce an immune
response37,45—penicillins have been shown to bind pro-
teins45,46 to form hapten-carrier complexes, which may
in turn elicit a T cell response.47 Drugs may also non-cova-
lently interact with MHC molecules and alter the reper-
toire of bound peptides leading to presentation of antigens
to which the host has not been previously tolerized. For
example, abacavir has been shown to bind non-covalently
within the F pocket of the antigen binding cleft of HLA-B*
57:01, altering its peptide specificity and leading to a CD8þ
T cell-mediated hypersensitivity response.48–50
It is increasingly recognized that the involvement of
HLA variation in hypersensitivity reactions goes beyond
peptide specificity. Other factors, such as effects on HLA
expression that influence the strength of the immune
response, have also been described.51 The analysis of
eQTLs based on the data of the eQTLGen Consortium22 re-
vealed that the lead SNP rs114892859 identified in our
GWAS of penicillin allergy appears to be associated withn Journal of Human Genetics 107, 612–621, October 1, 2020 617
the expression of several nearby genes, including expres-
sion of bothHLA-B andHLA-C, and an even stronger effect
on RNA levels of PSORS1C3 and MICA (Table S2). Variants
in PSORS1C3 have been associated with the risk of allopu-
rinol-, carbamazepine-, and phenytoin-induced SJS/TEN
hypersensitivity reactions52 andMICA encodes the protein
MHC class I polypeptide-related sequence A53 which has
been implicated in immune surveillance.54,55 Our findings
therefore support the observation that variants associated
with expression of HLA genes may contribute to the devel-
opment of hypersensitivity reactions.
We also detected an association with variants in PTPN22
on chromosome 1. PTPN22 encodes a tyrosine phospha-
tase involved in the regulation of immune cell
signaling.56 The lead missense variant rs2476601 has
previously been associated with several autoimmune dis-
eases57 and is a risk allele for rheumatoid arthritis.58 Inter-
estingly, this variant was also recently shown to be associ-
ated with drug-induced liver injury (DILI).59 The
association with the rs2476601 variant was strongest for
cases of amoxicillin- and clavulanic acid-associated liver
injury (OR 1.62, p value 4.0 3 106). Case subjects in
this study were clinically sourced and comprehensively
phenotyped, which suggests that our self-reported peni-
cillin allergy phenotype might also capture signal related
to more severe forms of beta-lactam hypersensitivity. How-
ever, the effect of this variant on penicillin allergy in the
current study is relatively small (OR 1.09) and its role in
the development of allergic reactions needs further studies.
A genetic correlation analysis of the penicillin allergy
GWAS results in the current study revealed overlap with
rheumatoid arthritis, even when excluding the PTPN22
region from the analysis. Furthermore, we identified a ge-
netic correlation with psoriasis, another autoimmune dis-
ease. Both psoriasis and psoriatic arthritis also have associ-
ations with HLA-B alleles.60,61 This indicates a possible
underlying autoimmune factor in the development of
the penicillin allergy phenotype investigated in our study.
Studies have suggested that penicillin allergy labels are
acquired in childhood and of children labeled as penicillin
allergic, 75% have acquired this label by age 3.8 In
addition, approximately 10% of patients tested per year
will lose their skin test reactivity, meaning that by adult-
hood >95% of allergy labels can be removed with formal
testing. The main limitation of this study is the unverified
nature of the phenotypes extracted from EHRs and self-
reported data in the biobanks. Previous work has found
that most (90%–95%) individuals labeled as having beta-
lactam hypersensitivity may not actually have true hyper-
sensitivity by adulthood when they more commonly
undergo validated testing.7,8,62,63 However, we believe
that the phenotype we have studied is valid for several
reasons.7,62 The most commonly reported penicillin al-
lergy is delayed-type allergy, which usually manifests as a
transient benign rash that does not recur on rechallenge
many years later.7,62,64 Furthermore, many individuals
who were once labeled as having IgE-mediated penicillin618 The American Journal of Human Genetics 107, 612–621, Octobeallergy develop tolerance over time.7 In both of these cases,
a true penicillin-induced reaction occurred initially, even if
tolerance develops subsequently. Our phenotype therefore
could represent individuals that experienced a reaction
associated to penicillin when they were previously
exposed, but who may, over time, tolerate penicillin
administration. A delayed rash is themost common self-re-
ported reaction seen in association with penicillin,7,62,64
which is frequently a T cell-mediated process. The results
from our in silico analyses, which link HLA-B*55:01 to
T cell biology, would support this observation. Therefore,
we posit that the association with the HLA-B*55:01 allele
may represent a predisposition to an immune response
associated with penicillin which does not appear to be
associated with a severe immediate or delayed reaction
and which may wane with time.
Despite the possibility that some cases in our study may
be misclassified, we detect a robust HLA association that
was replicated in several independent cohorts against
related phenotypes. The increased power arising from bio-
bank-scale sample sizes therefore mitigates some of the
challenges associated with EHR data. The robustness of
the genetic signal across cohorts with orthogonal pheno-
typing methods, ranging from EHR-sourced in EstBB and
BioVU to various forms of self-reported data in UKBB and
23andMe, also supports a true association. Finally, the
modest effect size of the HLA-B*55:01 allele (OR 1.33),
particularly when compared to effect sizes of HLA alleles
with established pharmacogenetic relevance,65–67 suggests
that this variant has limited predictive value. However,
further phenotypic refinement, including investigation
of specific penicillin derivatives and specific types of
drug reactions, may yield more clinically actionable
insight.
In summary, we have leveraged data from four large-
scale cohorts, including more than 100,000 case subjects,
to provide insights into the genetic architecture of self-re-
ported penicillin allergy and to provide robust evidence
implicating the HLA-B*55:01 allele in this condition.
Further studies are necessary to determine the precise un-
derlying immune processes and how these change over
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5. Böhm, R., and Cascorbi, I. (2016). Pharmacogenetics and pre-
dictive testing of drug hypersensitivity reactions. Front. Phar-
macol. 7, 396.
6. Iasella, C.J., Johnson, H.J., and Dunn, M.A. (2017). Adverse
Drug Reactions: Type A (Intrinsic) or Type B (Idiosyncratic).
Clin. Liver Dis. 21, 73–87.
7. Blumenthal, K.G., Peter, J.G., Trubiano, J.A., and Phillips, E.J.
(2019). Antibiotic allergy. Lancet 393, 183–198.
8. Castells, M., Khan, D.A., and Phillips, E.J. (2019). Penicillin
Allergy. N. Engl. J. Med. 381, 2338–2351.
9. Mirakian, R., Leech, S.C., Krishna, M.T., Richter, A.G., Huber,
P.A.J., Farooque, S., Khan, N., Pirmohamed, M., Clark, A.T.,
Nasser, S.M.; and Standards of Care Committee of the British
Society for Allergy and Clinical Immunology (2015). Manage-
ment of allergy to penicillins and other beta-lactams. Clin.
Exp. Allergy 45, 300–327.
10. Drug and Therapeutics Bulletin (2017). Penicillin allergy-get-
ting the label right. BMJ 358, j3402.n Journal of Human Genetics 107, 612–621, October 1, 2020 619
11. Roden, D.M., Pulley, J.M., Basford, M.A., Bernard, G.R., Clay-
ton, E.W., Balser, J.R., and Masys, D.R. (2008). Development
of a large-scale de-identified DNA biobank to enable personal-
ized medicine. Clin. Pharmacol. Ther. 84, 362–369.
12. Mitt, M., Kals, M., Pärn, K., Gabriel, S.B., Lander, E.S., Palo-
tie, A., Ripatti, S., Morris, A.P., Metspalu, A., Esko, T., et al.
(2017). Improved imputation accuracy of rare and low-fre-
quency variants using population-specific high-coverage
WGS-based imputation reference panel. Eur. J. Hum. Genet.
25, 869–876.
13. Kals, M., Nikopensius, T., Läll, K., Pärn, K., Sikka, T.T., Suvi-
saari, J., Salomaa, V., Ripatti, S., Palotie, A., Metspalu, A.,
et al. (2019). Advantages of genotype imputation with ethni-
cally matched reference panel for rare variant association an-
alyses. bioRxiv. https://doi.org/10.1101/579201.
14. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T.,
Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O’Connell,
J., et al. (2018). The UK Biobank resource with deep phenotyp-
ing and genomic data. Nature 562, 203–209.
15. Zhou, W., Nielsen, J.B., Fritsche, L.G., Dey, R., Gabrielsen,
M.E., Wolford, B.N., LeFaive, J., VandeHaar, P., Gagliano,
S.A., Gifford, A., et al. (2018). Efficiently controlling for
case-control imbalance and sample relatedness in large-scale
genetic association studies. Nat. Genet. 50, 1335–1341.
16. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and
efficient meta-analysis of genomewide association scans. Bio-
informatics 26, 2190–2191.
17. Jia, X., Han, B., Onengut-Gumuscu, S., Chen, W.-M., Concan-
non, P.J., Rich, S.S., Raychaudhuri, S., and de Bakker, P.I.W.
(2013). Imputing amino acid polymorphisms in human
leukocyte antigens. PLoS ONE 8, e64683.
18. Dilthey, A., Leslie, S., Moutsianas, L., Shen, J., Cox, C., Nelson,
M.R., and McVean, G. (2013). Multi-population classical HLA
type imputation. PLoS Comput. Biol. 9, e1002877.
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22. Võsa, U., Claringbould, A., Westra, H.-J., Bonder, M.J., Deelen,
P., Zeng, B., Kirsten, H., Saha, A., Kreuzhuber, R., Kasela, S.,
et al. (2018). Unraveling the polygenic architecture of com-
plex traits using blood eQTL metaanalysis. bioRxiv. https://
doi.org/10.1101/447367.
23. Ward, L.D., and Kellis, M. (2012). HaploReg: a resource for
exploring chromatin states, conservation, and regulatory
motif alterationswithin sets of genetically linked variants. Nu-
cleic Acids Res. 40, D930–D934.
24. Kundaje, A., Meuleman,W., Ernst, J., Bilenky, M., Yen, A., Her-
avi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., Ziller,
M.J., et al.; Roadmap Epigenomics Consortium (2015). Inte-
grative analysis of 111 reference human epigenomes. Nature
518, 317–330.
25. Myers, R.M., Stamatoyannopoulos, J., Snyder, M., Dunham, I.,
Hardison, R.C., Bernstein, B.E., Gingeras, T.R., Kent, W.J., Bir-
ney, E.,Wold, B., et al.; ENCODE Project Consortium (2011). A620 The American Journal of Human Genetics 107, 612–621, Octobeuser’s guide to the encyclopedia of DNA elements (ENCODE).
PLoS Biol. 9, e1001046.
26. Rentzsch, P., Witten, D., Cooper, G.M., Shendure, J., and
Kircher, M. (2019). CADD: predicting the deleteriousness of
variants throughout the human genome. Nucleic Acids Res.
47 (D1), D886–D894.
27. Kircher, M., Witten, D.M., Jain, P., O’Roak, B.J., Cooper, G.M.,
and Shendure, J. (2014). A general framework for estimating
the relative pathogenicity of human genetic variants. Nat.
Genet. 46, 310–315.
28. Marsh, S.G.E., Albert, E.D., Bodmer, W.F., Bontrop, R.E., Du-
pont, B., Erlich, H.A., Fernández-Viña, M., Geraghty, D.E.,
Holdsworth, R., Hurley, C.K., et al. (2010). Nomenclature for
factors of the HLA system, 2010. Tissue Antigens 75, 291–455.
29. Koscielny, G., An, P., Carvalho-Silva, D., Cham, J.A., Fumis, L.,
Gasparyan, R., Hasan, S., Karamanis, N., Maguire, M., Papa, E.,
et al. (2017). Open Targets: a platform for therapeutic target
identification and validation. Nucleic Acids Res. 45 (D1),
D985–D994.
30. Zheng, J., Erzurumluoglu, A.M., Elsworth, B.L., Kemp, J.P.,
Howe, L., Haycock, P.C., Hemani, G., Tansey, K., Laurin, C.,
Pourcain, B.S., et al.; Early Genetics and Lifecourse Epidemi-
ology (EAGLE) Eczema Consortium (2017). LD Hub: a central-
ized database and web interface to perform LD score regres-
sion that maximizes the potential of summary level GWAS
data for SNP heritability and genetic correlation analysis. Bio-
informatics 33, 272–279.
31. Williams, T.M. (2001). Human leukocyte antigen gene poly-
morphism and the histocompatibility laboratory. J. Mol. Di-
agn. 3, 98–104.
32. Chaplin, D.D. (2010). Overview of the immune response.
J. Allergy Clin. Immunol. 125 (2, Suppl 2), S3–S23.
33. Illing, P.T., Purcell, A.W., and McCluskey, J. (2017). The role of
HLA genes in pharmacogenomics: unravelling HLA associated
adverse drug reactions. Immunogenetics 69, 617–630.
34. Pavlos, R., Mallal, S., and Phillips, E. (2012). HLA and pharma-
cogenetics of drug hypersensitivity. Pharmacogenomics 13,
1285–1306.
35. Negrini, S., and Becquemont, L. (2017). HLA-associated drug
hypersensitivity and the prediction of adverse drug reactions.
Pharmacogenomics 18, 1441–1457.
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